|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
9/5/2012 8:00:34 AM
There is nothing like compensation and perks to irritate shareholders. Consider Phillip Frost, who is chairman of Teva Pharmaceuticals and is scheduled to receive a 75 percent increase in salary, which would jump to $900,000 annually, as well as another $700,000 for using his private jet. But there is more, Globes reports shareholders are also being asked to approve an additional $298,000, which would bring his travel expenses in 2011 to $1 million. The increases are part of a move to boost director salaries by an average of $76,000 a year, to $190,000, plus another $500 for every board meeting, which would actually be unchanged from previous years. The general shareholder meeting is scheduled for next week, but Platinum Investment Portfolio Management ceo Gabi Haber sent a letter to Teva directors, arguing they should not raise their salaries or approve Frost’s travel expenses by his private jet, Globes writes.
|
|
|
|
|
|
|
|
|
|
|